Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV002928930 | SCV003274159 | uncertain significance | not provided | 2024-12-09 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 941 of the RTTN protein (p.Val941Leu). This variant is present in population databases (rs199575994, gnomAD 0.09%). This variant has not been reported in the literature in individuals affected with RTTN-related conditions. ClinVar contains an entry for this variant (Variation ID: 2064907). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt RTTN protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
| Ambry Genetics | RCV002953780 | SCV003579676 | uncertain significance | Inborn genetic diseases | 2022-06-16 | criteria provided, single submitter | clinical testing | The c.2821G>C (p.V941L) alteration is located in exon 22 (coding exon 22) of the RTTN gene. This alteration results from a G to C substitution at nucleotide position 2821, causing the valine (V) at amino acid position 941 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Ce |
RCV002928930 | SCV004143268 | likely benign | not provided | 2023-02-01 | criteria provided, single submitter | clinical testing | RTTN: BP4 |